Literature DB >> 24089379

Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment.

James F Markworth1, Luke Vella, Benjamin S Lingard, Dedreia L Tull, Thusitha W Rupasinghe, Andrew J Sinclair, Krishna Rao Maddipati, David Cameron-Smith.   

Abstract

Classical proinflammatory eicosanoids, and more recently discovered lipid mediators with anti-inflammatory and proresolving bioactivity, exert a complex role in the initiation, control, and resolution of inflammation. Using a targeted lipidomics approach, we investigated circulating lipid mediator responses to resistance exercise and treatment with the NSAID ibuprofen. Human subjects undertook a single bout of unaccustomed resistance exercise (80% of one repetition maximum) following oral ingestion of ibuprofen (400 mg) or placebo control. Venous blood was collected during early recovery (0-3 h and 24 h postexercise), and serum lipid mediator composition was analyzed by LC-MS-based targeted lipidomics. Postexercise recovery was characterized by elevated levels of cyclooxygenase (COX)-1 and 2-derived prostanoids (TXB2, PGE2, PGD2, PGF2α, and PGI2), lipooxygenase (5-LOX, 12-LOX, and 15-LOX)-derived hydroxyeicosatetraenoic acids (HETEs), and leukotrienes (e.g., LTB4), and epoxygenase (CYP)-derived epoxy/dihydroxy eicosatrienoic acids (EpETrEs/DiHETrEs). Additionally, we detected elevated levels of bioactive lipid mediators with anti-inflammatory and proresolving properties, including arachidonic acid-derived lipoxins (LXA4 and LXB4), and the EPA (E-series) and DHA (D-series)-derived resolvins (RvD1 and RvE1), and protectins (PD1 isomer 10S, 17S-diHDoHE). Ibuprofen treatment blocked exercise-induced increases in COX-1 and COX-2-derived prostanoids but also resulted in off-target reductions in leukotriene biosynthesis, and a diminished proresolving lipid mediator response. CYP pathway product metabolism was also altered by ibuprofen treatment, as indicated by elevated postexercise serum 5,6-DiHETrE and 8,9-DiHETrE only in those receiving ibuprofen. These findings characterize the blood inflammatory lipid mediator response to unaccustomed resistance exercise in humans and show that acute proinflammatory signals are mechanistically linked to the induction of a biological active inflammatory resolution program, regulated by proresolving lipid mediators during postexercise recovery.

Entities:  

Keywords:  eicosanoid; exercise; inflammation; nonsteroidal anti-inflammatory drug; resolution

Mesh:

Substances:

Year:  2013        PMID: 24089379      PMCID: PMC3882565          DOI: 10.1152/ajpregu.00128.2013

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  110 in total

1.  Effect of a cyclooxygenase-2 inhibitor on postexercise muscle protein synthesis in humans.

Authors:  Nicholas A Burd; Jared M Dickinson; Jennifer K Lemoine; Chad C Carroll; Bridget E Sullivan; Jacob M Haus; Bozena Jemiolo; Scott W Trappe; Gordon M Hughes; Charles E Sanders; Todd A Trappe
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-11-24       Impact factor: 4.310

2.  Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids.

Authors:  M E Brezinski; C N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  Local NSAID infusion does not affect protein synthesis and gene expression in human muscle after eccentric exercise.

Authors:  U R Mikkelsen; P Schjerling; I C Helmark; S Reitelseder; L Holm; D Skovgaard; H Langberg; M Kjaer; K M Heinemeier
Journal:  Scand J Med Sci Sports       Date:  2010-08-24       Impact factor: 4.221

4.  NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis.

Authors:  Wei Shen; Yong Li; Ying Tang; James Cummins; Johnny Huard
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

5.  Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis.

Authors:  T A Trappe; F White; C P Lambert; D Cesar; M Hellerstein; W J Evans
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-03       Impact factor: 4.310

6.  Ginger (Zingiber officinale) reduces muscle pain caused by eccentric exercise.

Authors:  Christopher D Black; Matthew P Herring; David J Hurley; Patrick J O'Connor
Journal:  J Pain       Date:  2010-04-24       Impact factor: 5.820

7.  Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion.

Authors:  Brenda A Bondesen; Kristen A Jones; Wayne C Glasgow; Grace K Pavlath
Journal:  FASEB J       Date:  2007-05-08       Impact factor: 5.191

8.  Effect of prolonged exercise on plasma prostaglandin levels.

Authors:  L M Demers; T S Harrison; D R Halbert; R J Santen
Journal:  Prostaglandins Med       Date:  1981-04

Review 9.  12/15-lipoxygenase during the regulation of inflammation, immunity, and self-tolerance.

Authors:  Stefan Uderhardt; Gerhard Krönke
Journal:  J Mol Med (Berl)       Date:  2012-09-15       Impact factor: 4.599

10.  Myocellular enzyme leakage, polymorphonuclear neutrophil activation and delayed onset muscle soreness induced by isokinetic eccentric exercise.

Authors:  J L Croisier; G Camus; G Deby-Dupont; F Bertrand; C Lhermerout; J M Crielaard; A Juchmès-Ferir; C Deby; A Albert; M Lamy
Journal:  Arch Physiol Biochem       Date:  1996       Impact factor: 4.076

View more
  59 in total

Review 1.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors:  Johan Kreuger; Mia Phillipson
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

Review 2.  Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.

Authors:  Charles N Serhan
Journal:  FASEB J       Date:  2017-01-13       Impact factor: 5.191

Review 3.  Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.

Authors:  Nan Chiang; Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-31

Review 4.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

Authors:  Charles N Serhan; Bruce D Levy
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 5.  The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Semin Immunol       Date:  2015-04-07       Impact factor: 11.130

Review 6.  The impact of exercise training on adipose tissue remodelling in cancer cachexia.

Authors:  Rita Ferreira; Rita Nogueira-Ferreira; Rui Vitorino; Lúcio Lara Santos; Daniel Moreira-Gonçalves
Journal:  Porto Biomed J       Date:  2017-06-11

7.  Naproxen induces type X collagen expression in human bone-marrow-derived mesenchymal stem cells through the upregulation of 5-lipoxygenase.

Authors:  Abdulrahman M Alaseem; Padma Madiraju; Sultan A Aldebeyan; Hussain Noorwali; John Antoniou; Fackson Mwale
Journal:  Tissue Eng Part A       Date:  2014-10-23       Impact factor: 3.845

8.  Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid.

Authors:  James F Markworth; Gunveen Kaur; Eliza G Miller; Amy E Larsen; Andrew J Sinclair; Krishna Rao Maddipati; David Cameron-Smith
Journal:  FASEB J       Date:  2016-07-26       Impact factor: 5.191

9.  Human lung fibroblasts produce proresolving peroxisome proliferator-activated receptor-γ ligands in a cyclooxygenase-2-dependent manner.

Authors:  Shannon H Lacy; Collynn F Woeller; Thomas H Thatcher; Krishna Rao Maddipati; Kenneth V Honn; Patricia J Sime; Richard P Phipps
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-09       Impact factor: 5.464

Review 10.  Macrophage Proresolving Mediators-the When and Where.

Authors:  Jesmond Dalli; Charles Serhan
Journal:  Microbiol Spectr       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.